These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 23045227

  • 1. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
    Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
    [Abstract] [Full Text] [Related]

  • 2. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
    Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X.
    Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
    [Abstract] [Full Text] [Related]

  • 5. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, British Society for Rheumatology Biologics Register.
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [Abstract] [Full Text] [Related]

  • 7. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
    Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loët X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X.
    Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
    [Abstract] [Full Text] [Related]

  • 8. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
    Quartuccio L, Salvin S, Saracco M, Lombardi S, Fabris M, Mansutti E, Maset M, Pellerito S, De Vita S.
    Reumatismo; 2009 Sep; 61(3):182-6. PubMed ID: 19888503
    [Abstract] [Full Text] [Related]

  • 9. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [Abstract] [Full Text] [Related]

  • 10. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 11. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Clin Exp Rheumatol; 2011 May; 29(6):991-7. PubMed ID: 22133052
    [Abstract] [Full Text] [Related]

  • 12. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.
    Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loët X, Sibilia J, Tebib J, Mariette X, Constantin A.
    Rheumatology (Oxford); 2013 Apr; 52(4):636-41. PubMed ID: 23264555
    [Abstract] [Full Text] [Related]

  • 13. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [Abstract] [Full Text] [Related]

  • 14. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
    Couderc M, Gottenberg JE, Mariette X, Pereira B, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Soubrier M, Club Rhumatismes et Inflammations.
    Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
    [Abstract] [Full Text] [Related]

  • 15. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A, Szabó Z, Szamosi S, Bodnár N, Végh E, Gergely L, Szucs G, Szántó S, Szekanecz Z.
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [Abstract] [Full Text] [Related]

  • 16. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loët X, Marcelli C, Bardin T, Pane I, Baron G, Mariette X.
    Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
    [Abstract] [Full Text] [Related]

  • 17. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R, MIRA Study Group.
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [Abstract] [Full Text] [Related]

  • 18. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
    Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM.
    Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
    [Abstract] [Full Text] [Related]

  • 19. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S.
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.